Quick Search

  Wholesaler/Distributor Registration   l  My Cart   l   My Account  l  Home

 
Brands
  Pharmacist Nutriceuticals®
  USA Best®
  USA LABORATORIES®
  USA SPORTS LABS®
Products
  Health Concerns
  Sexual Health
  Specialty Supplements
  Vitamins & Minerals
  --------------------------------------------
  Weight Loss
  --------------------------------------------
  Children's
  --------------------------------------------
  Female
  Male
  --------------------------------------------
  Sports & Athletic Nutrition
  Extreme Hardcore Body Building
  Body Shaping
  Amino Acids
  Proteins
  Carbohydrates
  --------------------------------------------
  Food Bars
  --------------------------------------------
  Branded Ingredients
  --------------------------------------------
  Press Releases
  --------------------------------------------
  Employment
  Company Policy
MAXIMUM MALE™ (Yocyclipin-V®) [click to enlarge]
USALMM30C - 2#

MSRP: $44.99
Internet Direct: $39.99

Bottles:


30 Capsules
with (YOCYCLIPIN-V®)
Pharmacist Formulated Yohimbe, Ginseng, Kava Kava, Ginkgo Biloba, Plus More!

Pharmacist References:


YOCYCLOPIN-V® References:
1. Duke J. CRC Handbook of Medicinal of Herbs. Boca Raton, FL: CRC Press, 1985, 351.
2. Riley AJ. Yohimbine in the treatment of erectile disorder. Br J Clin Pract 1994;48:133-36.
3. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol 1998;159:433-36.
4. Carey MP, Johnson BT. Effectiveness of yohimbine in the treatment of erectile disorder: Four meta-analytic integrations. Arch Sex Behav 1996;25:341.
5. Kunelius P, Hakkinen J, Lukkarinen O. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urol 1997;49:441-44.
6. Mann K, Klingler T, Noe S, et al. Effect of yohimbine on sexual experiences and nocturnal tumescence and rigidity in erectile dysfunction. Arch Sex Behav 1996;25:1-16.
7. Goldberg KA. Yohimbine in the treatment of male erectile sexual dysfunction-a clinical review. Today's Ther Trends J New Dev Clin Med 1996;14:25-33.
8. Drug Facts and Comparisons. St. Louis: Facts and Comparisons, 1998, 3659.
9. Blumenthal M, Busse WR, Goldberg A, et al, eds. The Complete Commission E Monographs: Theraupeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998, 382-83.
10. Friesen K, Palatrick W, Tenenbein M. Benign course after massive ingestion of yohimbine. Emerst Med 1993;11:287-88.
11. Bremner JD, Innis RB, Ng CK, et al. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administriation in combat-related posttraumatic stress disorder. Arch Gen Psychiatry 1997;54:246-54.
12. Charney DS, Woods SW, Goodman Wk and Heninger GR. Neurobiological mechanisms of panic anxiety. Biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987;144:1030-36.
13. Cappiello A, McDougle CJ, Maleson RT, et al. Yohimbine augementation of fluvoxamine in refratic depression: A single-blind study. Biol Psychol 1995;38:765-67.

Selenium References:
1. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996;276:1957-63.
2. Yoshizawa K, Wilett WC, Morris SJ, et al. Study of prediagnostic selenium levels in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-24.
3. Yu S-Y, Li W-G, Zhu Y-J, et a. Chemoprevention trial of human hepatitis with selenium supplementation in China. Biol Trace Element Res 1989;20:15-20.
4. Peretz A, Neve J, Desmedt J, et al. Lymphocyte response is enhanced by supplementation of elde subjects with selenium-enriched yeast. Am J Clin Nutri 1991;53:1323-28.
5. Scott R, Mocpherson A, Yates RWS, et al. The effect of oral selenium supplementation on human sperm motitlity. Br J Urol 1998;82:76-80.
6. Dworkin BM. Selenium deficiency in HIV infection and the acquired immunodeficiency syndrome (AIDS). Chem Biol Iteract 1994;91:181-869.
7. Moore JA, Noiva R, Wells IC. Selenium concentrations in plasma of patients with arteriographically defined coronary atherosclerosis. Clin Chem 1984;30:1171-73.
8. Contempre B, Dumont JE, Ngo B, et al. Effects of selenium supplementation in hypothyroid subject of an iodine and selenium deficient area: The possible danger of indiscriminate supplementation of iodine deficient subjects with selenium. J Clin Endocrinol Metabol 1991;73:213-15.

Vitamin E References:
1. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450-56.
2. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1444-49.
3. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-86.
4. Christen S, Woodall AA, Shigenage MK, Southwell-Keely, Duncan MW, Ames BN. Gamma-tocopherol traps mutagenic electrophiles such as NO+ and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci 1997;94:3217-22.
5. Rimm E. Micronutrients, Coronary Heart disease and cancer: Should we all be on supplements? Presented at the 60th Annual Biology Colloquium, Oregon State University, February 25, 1999.

Ginglo Biloba References::
1. Drieu K. Preparation and definition of Ginkgo biloba extract. In: Rokan (Ginkgo biloba): Recent Results in Pharmacology and Clinic, ed. EW Funfgeld. Berlin: Springer-Verlag, 32-36.
2. Krieglstein J. Neuroprotective properties of Ginkgo biloba--constituents. Zeitschrift Phytother 1994;15:92-96.
3. Bruno C, Cuppini R, et al. Regeneration of motor nerves in bilobalide-treated rats. Planta Medica 1993;59:302-7.
4. Clostre F. From the body to the cellular membranes: the different levels of pharmacological actions Ginkgo biloba extract. In Rokan ( Ginkgo biloba): Recent Results in Pharmacology and Clinic, ed Funfgeld. Berlin: Springer-Verlag, 1988, 180-98.
5. Jung F, Mrowietz C, et al. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation volunteers. Arzneim-Forsch Drug Res 1990;40:589-93.
6. Itil Eralp E, Tsambis E, et a. Central nervous system effects of Ginkgo biloba, a plant extract. A J Therapeutics 1996;3:63-73.
7. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American Egb Study Group. JAMA 1997;278:1327-32.
8. Hofferbeth B. The efficacy of Egb 761 in patients with senile dementia of the Alzheimer type, a double-blind, place-bo-controlled study on different levels of investigation. Human Psychopharmacol 1994;9:215-22.
9. Kanowski S, Hermann W, Stephan K, et al. Proof of efficacy of the Ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimers type or multi-infarct demential. Pharmacopsychiarty 1996;29:47-56.
10. Ferrandini C, Droy=Lefaix MT, Christen Y, eds. Ginkgo biloba Extract (Egb 761) as a Free Radic Scavenger. Paris: Elsevier, 1993.
11. Lebuisson DA, Leroy L, Rigal G. Treatment of senile macular degeneration with Ginkgo biloba extract. A preliminary double-blind, drug versus placebo study. Presse Med 1986;15:1556-58 [in French].
12. Lanthony P, Cosson JP. Evolution of color vision in diabetic retinopathy treated by extract of Ginkgo biloba. J Fr Ophthalmol
1988;11:671-74 [in French].
13. Harman D. Free radical theory of aging: a hypothesis on pathogenesis of sevile dementia of the Alzheimer's type. Age 1993;16:23-30.
14. Schubert H, Halama P. Depressive episode primarily unresponsive to therapy in elderly patients: Efficacy of Ginkgo biloba extract (Egb 761) in combination with antidepressants. Geriatr Forsch 1993;3:45-53.
15. Lamant V, Mauco G, et al. Inhibition of the metabolism of platelet-activating factor (PAF-acether) three specific antagonists from Ginkgo biloba. Biochem Pharmacol 1987;36:2749-52.
16. Kroegel C, The potential pathophyisological role an therapeutic implications of platelet activating factor in diseases. Klir Wochenshr 1988;66:373-78.
17. Kroegel C, Kortsik C, et al. The pathophysiological role and therapeutic implications of platelet activating factor in diseases of aging. Drugs Aging 1992;2:345-55.
18. Kriegstein J. Neuroprotective properties of Ginkgo biloba-constituents. Zeitschrift Phytother 1994;15:92-9.
19. Haguenauer JP, Contenot F, Koskas H, Pierart H. Treatment of equilibrium problems with extract Ginkgo biloba. Multicenter, double-blind, placebo-controlled study. Presse Med 1986;15:1569-72 [in French].
20. Meyer B. A multicenter, double-blind, drug versus placebo study of Ginkgo biloba extract in the treatment of tinnitus. Press Med 1986;15:1562-64 [in French].
21. Blumenthal M, Busse WR, Goldberg A, et al eds. The Complete Commission E Monographs: Theraupeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998, 136-38.

Vitamin C References:
1. Balz F. Antioxiant vitamins and heart disease. Presented at the 60th Annual Biology Colloquium, Oregon State University, Corvallis, Oregon, February 25, 1999.
2. Hemilä H. Does vitamin C alleviate the symptoms of the common cold? A review of current evidence Scand J Infect Dis 1994;26:1-6
3. Taddei S, Virdis A, Ghaidoni L, et al. Vitamin C improves endotheoium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation
1998;97:2222-29
4. Chambers JC, McGregor A, Jean-Marie J, et al. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 1999;99:1156-60.
5. Taylor A. Cataract: relationship between nutrition and sxidation. J Am Coll Nutr 1993;12:138-46 [review].
6. Taylor A, Jacques PF, Nadler D, et al. Relationship in humans between ascorbic acid consumption and levels of total and reduced ascorbic acid in lens, aqueous humor, and plasma. Curr Eye Res 1991;10:751-59.
7. Jacques PF, Chylack LT Jr. Epidemiologic evidence of a role for the antioxidant vitamins and carotenoids in cataract prevention. Am J Clin Nutr 1991;53:352S-55S
8. Jacques PF, Chylack LT, McGandy RB, Hartz SC. Antioxidant status in persons with and without senile cataract. Arch Ophthalmol 1988;106:337-40.
9. Robertson JM, Donner AP, Trevithick JR. vitamin E intake and risk of cataracts in humans Ann Nrl Acad Sci 1989;570:372-82.
10. Seddon JM, Christen WG, Manson JE, et al. The use of vitamin supplements and the risk of cataract among US male physicians. Am J Public Health 1994;84:788-792.
11. Vincent TE, mendiratta S, may JM. Inhibition of aldose reductase in human erythrocytes by vitamin C. diabetes Res Clin Pract1 999;43:1-8.
12. Simon JA. Ascorbic acid and cholesterol gallstones. Med Hypotheses 1993;40:81-84.
13. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996;93:3704-709
14. Sandstead HH. Copper bioavailability and requirements. Am J clin Nutr 1982;35:809-14 [review].
15. Finley EB, Cerklewski FL. Influence of ascorbic acid supplementation on copper status in yound adult men. Am J Clin Nutr 1983;37:553-56.
16. Piesse JW. Nutritional factors in calcium containing kidney stones wiht particular emphasis on vitamin C. Int Clin Nutr Rev 1985;5(3):110-129 [review]
17. Ringsdorf WM, Cheraskin WM. Medical complications from ascorbic acid: review and interpretation (part one). J Holistic Med 1984;6(1):49-63.
18. Hoffer A. Ascorbic acid and kidney stones. Can Med Assoc J 1985;32:320 [letter]
19. Wandzilak TR, D'Andre SD, Davis PA, Williams HE. Effect of high dose vitamin C on urinary oxal levels. J Urol 1994;151:834-37.
20. Levine M. Vitamin C and optimal health. Presented at the February 25, 1999 60th Annual Biology Colloquium, Oregon State University, Corvallis, Oregon.
21. Levine M, Conry-Cantilena C, wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers:evidnece for a recommended dietary allowance. proc Natl Acad Sci USA 1996;93:3704-709.
22. Auer BL, Auer D, Rodgers AL. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. Eur J Clin Invest 1998;28:695-700.

Zinc References:
1. Mossad SB, Macknin ML, Medendorp SV, et al. Zinc gluconate lozenges for treating the common cold. Ann Int Med
1996;125:81-88.
2. Anonymous. Zinc lozenges reduce the duration of common cold symptoms. Nutr Rev 1997;55:82-88 [review].
3. Garland ML, Hagmeyer KO. The role of zinc lozenges in treatment of the common cold. Ann Pharmacother 1998;32:63-69 [review].
4. Macknin ML, Piedmonte M, Calendine C, et al. Zinc gluconate lozenges for treating the common cold in children. A randomized controlled trial. JAMA 1998;279:192-67.
5. Eby G. Where's the bias? Ann Intern Med 1998;128:75 [letter].
6. Petrus EJ, Lawson KA, Bucci LR, Blum K. Randomized, double-masked, placebo-controlled clinical study of the effectiveness of zinc acetate lozenges on common cold symptons in allergy-tested subjects. Curr Ther Res 1998;59:595-607.
7. Weismann K, Jakobsen JP, Weismann JE, et al. Zinc gluconate lozenges for common cold. A double-blind clinical trial. Dan Med Bull 1990;37:279-81.
8. Cherry FF, Sandstead HH, Rojas P, et al. Adolescent pregnancy: associations among body weight, zinc nutriture, and pregnancy outcome. Am J Clin Nutr 1989;50:945-54.
9. Goldenberg RL, Tamura T, Neggers Y, et al. The effect of zinc supplementation on pregnancy outcome. JAMA 1995;274:463-68.
10. Prasad A. Discovery of human zinc deficiency and studies in an experimental human model. Amer clin Nutr 1991;53:406-13 [review].
11. Chandra RK. Excessive intake of zinc impairs immune responses. JAMA 1984;252(11):1443.
12. Bush Al, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A8 amyloid formation by zinc. Science
1994;265:1464-65.
13. Potocnik FCV, van Rensburg SJ, Park C, et al. Zinc and platelet membrane microviscosity in Alzheimer's disease. S Afr Med J 1997;87:1116-19.
14. Prasad AS. Zinc in human health: an update. J Trace Elements Exper Med 1998;11:63-87.
15. Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion-a reversible cause of sideroblastic anemia and bone marrow depression. JAMA 1990;264:1441-43.
16. Resiser S, et al. Effect of copper intake on blood colesterol and its lipoprotein distribution in men. Nutr Rep Internat 1987;36(3):641-49.
17. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am Jclin Nutr 1995;61(suppl):621S-24S [review].
18. Fischer PWF, Girous A, Labbe MR. Effect of zinc supplementation on copper status in adult man. Am J Clin Nutr
1984;40(4):743-46.
19. Dawson EB, Albers J, McGanity WJ. Serum zinc change due to iron supplementation in teenage pregnancy. Am J Clin Nutr 1990;50:848-52.
20. Crofton RW, Gvozdanovic D, Gvozanovic S, et al. Inorganic zinc and the intestinal absorption of ferrous iron. Am J Clin Nutr 1989;50:141-44.
21. Argiratos V, Samman S. The effect of calcium carbonate and calcium citrate on the absorption of zinc in healthy female subjects. Eur J Clin Nutr 1994;48:198-204.
22. Spence H, Norris C, Williams D. Inhibitory effects of zinc on magnesium balance and magnesium absorption in man. J Am Coll Nutr 1994;13:479-84.
23. Brumas V, Hacht B, Filella M, Berthon G. Can N-acetyl-L-cysteine affect zinc metabolisms when used as a paracetamol antidote? Agents Actions 1992;36:278-88.


  • Back To List
  • Wholesaler/Distributor Registration   l  My Cart   l   My Account  l  Home  l  Return to Top of Page

        Nasvhille Chamber of Commerce Dickson County Chamber of Commerce U.S. Commercial Service

    *These statements have not been evaluated by the F.D.A. *USA Laboratories makes no representation or warranties concerning the use of our products for the diagnosis, cure, mitigation, treatment or prevention of any disease. *Seek advice from a health care provider before using this or any supplement product.

    Powered By LionZone Copyright © USA LABORATORIES, INC. All rights reserved.